CSF1R inhibitors for treatment of cancer and bone diseases

Details for Australian Patent Application No. 2008313727 (hide)

Owner Novartis AG

Inventors Wang, Weibo; Sutton, James; Sendzik, Martin

Agent Davies Collison Cave

Pub. Number AU-A-2008313727

PCT Pub. Number WO2009/050228

Priority 60/981,058 18.10.07 US

Filing date 16 October 2008

Wipo publication date 23 April 2009

International Classifications

A61K 31/4184 (2006.01)

A61K 31/4188 (2006.01)

A61K 31/428 (2006.01) - condensed with carbocyclic rings

A61K 31/429 (2006.01) - condensed with heterocyclic ring systems

A61K 31/47 (2006.01) - Quinolines

A61K 31/517 (2006.01) - ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine

A61P 9/10 (2006.01) Drugs for disorders of the cardiovascular system

A61P 13/12 (2006.01) Drugs for disorders of the urinary system

A61P 19/02 (2006.01) Drugs for skeletal disorders

A61P 35/00 (2006.01) Antineoplastic agents

Event Publications

8 April 2010 PCT application entered the National Phase

  PCT publication WO2009/050228 Priority application(s): WO2009/050228

22 April 2010 Corrigenda

  PCT applications that have entered the National Phase - Name Index Under the name Novartis AG, Application No. 2008313727, under INID (54), correct the title to read CSF-1R inhibitors for treatment of cancer and bone diseases

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2008313733-CGRP antagonists

2008313721-Method for producing a foaming agent